A
NAGE

AJOVista’s Niagen Bioscience NAGE Stock Holding History

AJOVista’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$64.1K Buy
17,552
+7,440
+74% +$23.4K 0.27% 92
2024
Q2 		$27.6K Buy
+10,112
New +$33.8K 0.08% 73

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

AJOVista's NAGE Position: Q3 2024 in Review

AJOVista increased its Niagen Bioscience (NAGE) stake by 74% in Q3 2024, buying an estimated $23.4K and bringing the position to 17,552 shares worth $64.1K. The position accounts for 0.27% of the portfolio, ranked #92.

AJOVista first reported a position in NAGE in Q2 2024 and has held it in 2 quarters since. 91 funds tracked by Wall St. Rank hold NAGE as of Q3 2024.

  • AJOVista held 17,552 shares of Niagen Bioscience worth $64.1K as of Q3 2024.
  • AJOVista bought 7,440 Niagen Bioscience shares in Q3 2024, an estimated $23.4K.
  • Niagen Bioscience made up 0.27% of AJOVista's portfolio in Q3 2024, its #92 holding.
  • AJOVista first reported a position in Niagen Bioscience in Q2 2024 and has held it in 2 quarters since.
  • 91 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2024.

Based on AJOVista's 13F filing for Q3 2024, filed 12 Nov 2024.